Alphagan P 0.15% Ophthalmic Solution
Alphagan P 0.15% is positioned as a potent topical alpha-2 adrenergic agonist for canine glaucoma, offering a higher brimonidine concentration together with a Purite preservative designed to limit ocular surface toxicity. For the specific use case of topical antiglaucoma therapy in dogs it is often preferred for acute or refractory intraocular pressure elevation compared with the 0.1% formulation because of stronger IOP reduction, and though it typically carries a premium versus generic brimonidine it delivers a consistent proprietary formulation that can reduce the need for adjunctive agents.
Stronger pressure drop
Purite-preserved sparkle
Stronger pressure drop
Purite-preserved sparkle
Review Summary
"Long-term users report Alphagan P 0.15% frequently reduces intraocular pressure in dogs and is generally well tolerated, though some pets experience mild ocular irritation or transient lethargy. Many owners and vets consider it effective as part of chronic glaucoma management when monitored."
Rapidly soothing touch
Contains brimonidine 0.15%, an alpha-2 agonist used to reduce intraocular pressure in humans and commonly used off-label in dogs under veterinary guidance.
Rapidly soothing touch
Contains brimonidine 0.15%, an alpha-2 agonist used to reduce intraocular pressure in humans and commonly used off-label in dogs under veterinary guidance.
Increased Safety & Security
Time-Saving Convenience
Alphagan P 0.15% is positioned as a potent topical alpha-2 adrenergic agonist for canine glaucoma, offering a higher brimonidine concentration together with a Purite preservative designed to limit ocular surface toxicity. For the specific use case of topical antiglaucoma therapy in dogs it is often preferred for acute or refractory intraocular pressure elevation compared with the 0.1% formulation because of stronger IOP reduction, and though it typically carries a premium versus generic brimonidine it delivers a consistent proprietary formulation that can reduce the need for adjunctive agents.
Stronger pressure drop
Purite-preserved sparkle
Rapidly soothing touch
Contains brimonidine 0.15%, an alpha-2 agonist used to reduce intraocular pressure in humans and commonly used off-label in dogs under veterinary guidance.
Formulated with Purite preservative to minimize ocular surface irritation compared with older preservatives.
Stronger pressure drop
Purite-preserved sparkle
Rapidly soothing touch
Contains brimonidine 0.15%, an alpha-2 agonist used to reduce intraocular pressure in humans and commonly used off-label in dogs under veterinary guidance.
Formulated with Purite preservative to minimize ocular surface irritation compared with older preservatives.
$60-100 CAD
Alphagan P 0.1% Ophthalmic Solution
Alphagan P 0.1% offers a lower-concentration, better-tolerated brimonidine option tailored for chronic management of glaucoma in dogs, retaining the same Purite preservative to minimize ocular irritation. Compared with the 0.15% product it trades some peak efficacy for improved systemic safety and often lower per-dose cost, making it a market-leading choice when long-term ocular surface health and owner compliance are priorities versus higher-strength or combination therapies.
Lower concentration calm
Milder systemic profile
Lower concentration calm
Milder systemic profile
Review Summary
"Owners using Alphagan P 0.1% repeatedly note reasonable IOP control with fewer stinging complaints than older formulations, but effectiveness can be variable between animals and occasional systemic side effects are reported. Overall it is seen as a useful, generally well-tolerated option for long-term use in many dogs."
Gentle daily comfort
Brimonidine 0.1% offers a lower concentration that may reduce systemic absorption potential while retaining IOP-lowering activity.
Gentle daily comfort
Brimonidine 0.1% offers a lower concentration that may reduce systemic absorption potential while retaining IOP-lowering activity.
Increased Safety & Security
Time-Saving Convenience
Alphagan P 0.1% offers a lower-concentration, better-tolerated brimonidine option tailored for chronic management of glaucoma in dogs, retaining the same Purite preservative to minimize ocular irritation. Compared with the 0.15% product it trades some peak efficacy for improved systemic safety and often lower per-dose cost, making it a market-leading choice when long-term ocular surface health and owner compliance are priorities versus higher-strength or combination therapies.
Lower concentration calm
Milder systemic profile
Gentle daily comfort
Brimonidine 0.1% offers a lower concentration that may reduce systemic absorption potential while retaining IOP-lowering activity.
Uses the same Purite preservative system for improved ocular tolerability.
Lower concentration calm
Milder systemic profile
Gentle daily comfort
Brimonidine 0.1% offers a lower concentration that may reduce systemic absorption potential while retaining IOP-lowering activity.
Uses the same Purite preservative system for improved ocular tolerability.
$50-90 CAD
Brimonidine Tartrate 0.2% Ophthalmic Solution
Brimonidine Tartrate 0.2% generic formulations represent the widely available, low-cost alpha-2 agonist option for canine glaucoma and deliver clinically useful IOP lowering comparable to branded brimonidine products. Financially and technically they undercut branded options such as Alphagan P and combination products, but the lack of specialized preservatives and potential for more frequent dosing can increase ancillary costs or the need for additional therapies in some canine patients.
Reliable IOP control
Single-agent classic
Reliable IOP control
Single-agent classic
Review Summary
"Users of brimonidine tartrate 0.2% say it can lower eye pressure in dogs but less consistently than some alternatives and is more likely to cause local irritation or drowsiness in sensitive animals. Many report it works in the short term but mixed results with long-term control."
Steady, no-frills drops
Generic brimonidine 0.2% provides an affordable alpha-2 agonist option for intraocular pressure control.
Steady, no-frills drops
Generic brimonidine 0.2% provides an affordable alpha-2 agonist option for intraocular pressure control.
Increased Safety & Security
Time-Saving Convenience
Brimonidine Tartrate 0.2% generic formulations represent the widely available, low-cost alpha-2 agonist option for canine glaucoma and deliver clinically useful IOP lowering comparable to branded brimonidine products. Financially and technically they undercut branded options such as Alphagan P and combination products, but the lack of specialized preservatives and potential for more frequent dosing can increase ancillary costs or the need for additional therapies in some canine patients.
Reliable IOP control
Single-agent classic
Steady, no-frills drops
Generic brimonidine 0.2% provides an affordable alpha-2 agonist option for intraocular pressure control.
Widely available from multiple manufacturers, with variability in preservatives and bottle design.
Reliable IOP control
Single-agent classic
Steady, no-frills drops
Generic brimonidine 0.2% provides an affordable alpha-2 agonist option for intraocular pressure control.
Widely available from multiple manufacturers, with variability in preservatives and bottle design.
$40-80 CAD
Iopidine 0.5% Ophthalmic Solution
Iopidine (apraclonidine 0.5%) is valued as a short-acting, potent alpha-2 agonist for rapid intraocular pressure control in dogs, making it a market leader for perioperative or acute interventions compared with chronic-use brimonidine formulations. Its technical advantage is rapid onset and strong initial IOP reduction, but tachyphylaxis and a higher likelihood of systemic adrenergic effects limit long-term use, so it is most advantageous when immediate pressure control can reduce expensive multi-drug regimens.
Short-term pressure rescue
High-potency burst
Short-term pressure rescue
High-potency burst
Review Summary
"Owners and clinicians using Iopidine (apraclonidine 0.5%) for repeated or perioperative use find it effective for short-term IOP drops, but many note diminished effect with prolonged use and occasional cardiovascular or behavioral side effects. It is generally viewed as a useful temporary agent rather than a long-term sole therapy."
Ideal for acute spikes
Iopidine contains apraclonidine 0.5%, an alpha-2 agonist often used for rapid or short-term IOP reduction.
Ideal for acute spikes
Iopidine contains apraclonidine 0.5%, an alpha-2 agonist often used for rapid or short-term IOP reduction.
Increased Safety & Security
Time-Saving Convenience
Iopidine (apraclonidine 0.5%) is valued as a short-acting, potent alpha-2 agonist for rapid intraocular pressure control in dogs, making it a market leader for perioperative or acute interventions compared with chronic-use brimonidine formulations. Its technical advantage is rapid onset and strong initial IOP reduction, but tachyphylaxis and a higher likelihood of systemic adrenergic effects limit long-term use, so it is most advantageous when immediate pressure control can reduce expensive multi-drug regimens.
Short-term pressure rescue
High-potency burst
Ideal for acute spikes
Iopidine contains apraclonidine 0.5%, an alpha-2 agonist often used for rapid or short-term IOP reduction.
Typically used perioperatively or for acute pressure control rather than long-term management due to tachyphylaxis risk.
Short-term pressure rescue
High-potency burst
Ideal for acute spikes
Iopidine contains apraclonidine 0.5%, an alpha-2 agonist often used for rapid or short-term IOP reduction.
Typically used perioperatively or for acute pressure control rather than long-term management due to tachyphylaxis risk.
$70-130 CAD
Combigan Ophthalmic Solution
Combigan combines brimonidine (an alpha-2 agonist) with timolol (a beta blocker) to provide additive IOP lowering and improved dosing convenience for dogs with glaucoma, often delivering greater pressure reduction per instillation than alpha-agonist monotherapy. From a financial and practical perspective it can be cost-saving by reducing the number of separate medications and improving owner adherence, but the beta-blocker component requires caution in patients with cardiac or respiratory disease, distinguishing it from pure alpha-agonist options like Alphagan P or Iopidine.
Dual-action reduction
Fewer applications needed
Dual-action reduction
Fewer applications needed
Review Summary
"Users of Combigan (brimonidine/timolol) report good IOP reduction in many dogs and appreciate the combination action, but some pets experience systemic beta-blocker effects (lethargy, respiratory signs) and not all respond long-term. Overall it is rated effective by most when prescribed with veterinary oversight."
Synergistic double-hit
Combigan combines brimonidine 0.2% with timolol 0.5% in a single fixed-dose formulation for dual-mechanism IOP lowering.
Synergistic double-hit
Combigan combines brimonidine 0.2% with timolol 0.5% in a single fixed-dose formulation for dual-mechanism IOP lowering.
Increased Safety & Security
Time-Saving Convenience
Combigan combines brimonidine (an alpha-2 agonist) with timolol (a beta blocker) to provide additive IOP lowering and improved dosing convenience for dogs with glaucoma, often delivering greater pressure reduction per instillation than alpha-agonist monotherapy. From a financial and practical perspective it can be cost-saving by reducing the number of separate medications and improving owner adherence, but the beta-blocker component requires caution in patients with cardiac or respiratory disease, distinguishing it from pure alpha-agonist options like Alphagan P or Iopidine.
Dual-action reduction
Fewer applications needed
Synergistic double-hit
Combigan combines brimonidine 0.2% with timolol 0.5% in a single fixed-dose formulation for dual-mechanism IOP lowering.
Combination dosing can improve convenience and adherence in chronic glaucoma cases when used under veterinary supervision.
Dual-action reduction
Fewer applications needed
Synergistic double-hit
Combigan combines brimonidine 0.2% with timolol 0.5% in a single fixed-dose formulation for dual-mechanism IOP lowering.
Combination dosing can improve convenience and adherence in chronic glaucoma cases when used under veterinary supervision.
$120-180 CAD